Evidence map›Paper›PMID 39886949›Full record

ArticleOncology reports2025

Evaluation of co‑inhibition of ErbB family kinases and PI3K for HPV‑negative head and neck squamous cell carcinoma.

Xinyan Geng, Shirin Azarbarzin, Zejia Yang, Rena G Lapidus, Xiaoxuan Fan, Yong Teng, Ranee Mehra, Kevin J Cullen, Hancai Dan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinyan GengMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Shirin AzarbarzinMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Zejia YangMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Rena G LapidusMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Xiaoxuan FanMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Yong TengDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30332, USA.
Ranee MehraMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Kevin J CullenMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Hancai DanMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Inhibition of castration resistant prostate cancer by targeting of the IKKbeta/AR signalingR01CA212094 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI DAN, HANCAI · 2017 to 2021
$1.8M
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC ProgressionR00CA149178 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI DAN, HANCAI · 2013 to 2015
$709k
Targeting PI3Kalpha beta and the ErbB family of protein-tyrosine kinases in cisplatin-resistant head and neck squamous cell carcinomas (HNSCC)R56DE030423 · NIDCR · UNIVERSITY OF MARYLAND BALTIMORE · PI CULLEN, KEVIN J., DAN, HANCAI · 2022 to 2022
$376k
NCI NIH HHS P30 CA134274NCI NIH HHS R00 CA149178NCI NIH HHS R01 CA212094NIDCR NIH HHS R56 DE030423
6 · The paper itself

Abstract

The ErbB/HER family of protein‑tyrosine kinases and PI3K represent crucial targets in the treatment of head and neck squamous cell carcinoma (HNSCC). A combination therapy of afatinib (ErbB inhibitor) and copanlisib (PI3K inhibitor), both Food and Drug Administration‑approved kinase inhibitors, can suppress the growth of human papillomavirus (HPV)‑positive HNSCC. The current study further evaluated the efficacy and clinical potential of this combination therapy for the treatment of HPV‑negative HNSCC

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsPhosphoinositide-3 Kinase InhibitorsPyrimidinesSquamous Cell Carcinoma of Head and NeckAfatinibAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMicePhosphatidylinositol 3-KinasesAfatinibcopanlisibERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesERBB3 protein, humanPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsPyrimidinesQuinazolinesReceptor, ErbB-3ErbB inhibitorhead and neck squamous cell carcinomaPI3K inhibitorstargeted therapies

Identifiers

PMID39886949
PMCPMC11800064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.